Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation Vancouver, BC, January 21, 2025--(T-Net)--Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new …